Prospective Observational Study on Predictors of Early On-treatment Response and Sustained Virological Response in a Cohort of Treatment naive HCV-infected Patients Treated With Pegylated Interferons.
Phase of Trial: Phase IV
Latest Information Update: 12 Aug 2016
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Peginterferon alfa-2b (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms PROPHESYS 3
- Sponsors Roche
- 01 Sep 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 30 Nov 2011 Planned end date changed from 1 Feb 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.
- 30 Nov 2011 Actual patients number (1613) added as reported by ClinicalTrials.gov.